Ignite Creation Date:
2025-12-24 @ 9:21 PM
Ignite Modification Date:
2025-12-26 @ 9:23 PM
Study NCT ID:
NCT00609804
Status:
COMPLETED
Last Update Posted:
2016-04-08
First Post:
2008-01-24
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Sorafenib and Erlotinib or Sorafenib Alone in Advanced Non-Small Cell Lung Cancer Progressing on Erlotinib
Sponsor:
SCRI Development Innovations, LLC
Organization:
Organization Data
Organization:
Class:
OTHER
Study ID:
SCRI LUN 162
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
OTHER
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None